BMY Bristol-Myers Squibb Company Co

54.21
+0.11  (0%)
Previous Close 54.10
Open 54.16
Price To book 6.18
Market Cap 89.31B
Shares 1,647,434,000
Volume 7,187,080
Short Ratio 2.81
Av. Daily Volume 9,256,720

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2018.
TG4010 and Opdivo
Phase 2 late breaker at ASCO June 5, 2017. Abstract LBA8507.
Opdivo + Yervoy
Malignant pleural mesothelioma (MPM)
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Solid tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017. Abstract 3003.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
PDUFA date under priority review August 2, 2017.
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
PDUFA date under priority review August 2, 2017.
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
PDUFA date under priority review August 2, 2017.
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
Phase 3 first overall survival (OS) positive data released April 3, 2017
CM - 067 Opdivo in combination with Yervoy
Melanoma
Phase 3 data released January 19, 2017.
Opdivo - ONO-4538-12
Gastric cancer
Phase 2 data due 2H 2018 – 1H 2019.
CM-568 - Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data due 1H 2018.
CM-651 – Opdivo + Yervoy
First-line Head and Neck Cancer
Phase 3 data due 2H 2018.
CM-602 – Opdivo + Elo + SOC
Myeloma
Phase 3 data due 2H 2017.
CM-459 – Opdivo
First-line Hepatocellular carcinoma (HCC) - cancer
Phase 3 data due 2Q or 3Q 2017.
CM-511 – Opdivo + Yervoy
First-line Melanoma
Phase 3 data due 1H 2018.
CM-451 – Opdivo + Yervoy
First-line Small cell lung cancer (SCLC)
Phase 3 data due 1H 2018.
CM-331– Opdivo
Second-line Small cell lung cancer (SCLC)
Phase 3 data due 2H 2018.
CM-238 – Opdivo (Adjuvant)
Melanoma
Phase 3 data due 1H 2018.
CM-227 – Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data due 2H 2017.
CM-214 – Opdivo + Yervoy
First-line Renal cell carcinoma (RCC)
Phase 3 data released April 3, 2017 - primary endpoint not met.
CM-143 – Opdivo
Second-line Glioblastoma (GBM) cancer
Phase 3 data due 1H 2018.
CM-078 – Opdivo
Second-line Non-small cell lung cancer (NSCLC)
Phase 2 data due 1H 2018.
CM-548 - Opdivo+SOC
First-line Glioblastoma (GBM) cancer
Urothelial Carcinoma - Bladder cancer
Opdivo (nivolumab)
Bladder cancer

Latest News

  1. 1Q17 Performance of Keytruda, Merck’s Blockbuster Drug
  2. With Stock Returns Of Over 205% in the Last Year, This Fund Is Proof That Hedge Funds Aren’t Going Anywhere
  3. Blog Coverage: Bristol-Myers Squibs Received EMA Validation of Sprycel for the Treatment in Children with Chronic Myelogenous Leukemia
  4. What Orencia Meant to BMY in 1Q17
  5. New Research Reports for Britol-Myers, Pricline & Phillips 66
  6. Top 5 Buys of Market-Beating Investors at Primecap Management
  7. Behind BMY’s Cardiovascular Performance in 1Q17
  8. Revisiting Bristol-Myers Squibb’s Virology in 1Q17
  9. European Medicines Agency Validates Application for Bristol-Myers Squibb’s Sprycel (dasatinib) in Children with Chronic Myelogenous Leukemia
  10. What Happened to Bristol-Myers Squibb’s Opdivo in 1Q17?
  11. The Hot Stock: Incyte Climbs
  12. Understanding Bristol-Myers Squibb’s Oncology Performance in 1Q17
  13. Biotech Movers: Fast Track Designation Sends Sage Shares Higher
  14. Behind Bristol-Myers Squibb’s 1Q17 Performance
  15. Inside Bristol-Myers Squibb’s Valuation after the 1Q17 Earnings
  16. What to watch at ASCO cancer conference
  17. Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017
  18. Eli Lilly: Worries Ahead In Patent Fight
  19. Cramer: Carl Icahn Was Right to Sell Apple at $95
  20. Eli Lilly: Has This Bloom Begun To Wilt?